The proposed Coordinating Center will participate with the selected Clinical Centers and the National Heart, Lung and Blood Institute (NHLBI) in the design and performance of a randomized clinical trail to determine the best clinically useful techniques to prevent or minimize alloimmunization as a cause of refractoriness to platelet transfusion. One or more treatment arms will be compared with a control arm of routinely prepared random-donor platelet concentrates and routinely prepared red cell products. The coordinating Center will provide data management, reporting services, data analysis, and overall study coordination and management, and coordinate the function of the Central Laboratory as decided by the investigators. The Coordinating Center will design the study forms, write the protocol and manual of operations, and plan and implement randomization and study quality control procedures. Monthly quality control reports will be sent to the Clinical Centers and the NHLBI. Detailed reports on the accumulating data and Clinical Center performance will be provided every six months to the Data and Safety Monitoring Board (DSMB). Other analyses as required by the DSMB and the NHLBI will also be provided. The Coordinating Center investigators will function as executive secretariat and collaborate with other investigators in analyzing the study data for presentation and publication.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL042824-03
Application #
3553370
Study Section
Special Emphasis Panel (SRC (KG))
Project Start
1989-08-01
Project End
1995-05-31
Budget Start
1991-07-15
Budget End
1992-05-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Public Health
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Slichter, Sherrill J; Bolgiano, Douglas; Kao, Kuo-Jang et al. (2011) Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev 25:102-10
Slichter, Sherrill J; Davis, Kathryn; Enright, Helen et al. (2005) Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105:4106-14
Enright, Helen; Davis, Kathryn; Gernsheimer, Terry et al. (2003) Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 43:1545-52
Olivieri, N F; Brittenham, G M (1998) Long-term trials of deferiprone in Cooley's anemia. Ann N Y Acad Sci 850:217-22
Olivieri, N F; Brittenham, G M; Matsui, D et al. (1995) Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 332:918-22
Brittenham, G M (1994) New advances in iron metabolism, iron deficiency, and iron overload. Curr Opin Hematol 1:101-6